HOME > TOP STORIES

TOP STORIES

ACADEMIA Medical Society Says “No” to Discontinuation of Theodur Despite Supply Struggle

February 5, 2025
REGULATORY PMD Act Set for Amendments Covering Issues Unaddressed over Past Decade: MHLW Official

February 4, 2025
BUSINESS Daiichi Sankyo Assigns COO Okuzawa as CEO from April

February 3, 2025
BUSINESS Julie Kim Tapped to Take Over Helm of Takeda in 2026

January 31, 2025
BUSINESS Takeda CEO Weber to Retire Next Year, Succeeded by US Head

January 30, 2025
BUSINESS Pfizer Japan Resolved to Drive Vaccine Demand, New Drug Launches: President

January 30, 2025
REGULATORY Pfizer’s Litfulo Braced for Price Cut after Cost-Effectiveness Assessment

January 30, 2025
REGULATORY MHLW Panel Finalizes NIP Inclusion of Shingles Jabs, OKs New Basic Immunization Plan

January 30, 2025
BUSINESS Nichi-Iko to Start Production Collaboration with Kyowa in FY2025: President

January 29, 2025
REGULATORY LDP-OK’ed Bill for PMD Act Amendment Specifies Launch of Innovative Drug Fund

January 28, 2025
BUSINESS Sanofi Stages V-Shaped Recovery in Vaccine Biz, Set for Growth with New Products Beyond Hib

January 27, 2025
BUSINESS MHLW Planning 10-Year Fund for Drug Discovery, Official Reveals at JPMA Meeting

January 24, 2025
REGULATORY MHLW Eyes 2 Biz Models as It Pushes Generic Industry Shakeup: Minister

January 23, 2025
BUSINESS Sanofi CEO Warns Off-Cycle Price Cuts Will Dilute Attractiveness of Japan Market

January 22, 2025
REGULATORY Astellas’ Xtandi on 2nd Drug List Up for IRA Price Negotiations

January 21, 2025
BUSINESS Nxera’s 50 Billion Yen Global Sales Goal “Conservative Figure”: Japan Chief

January 20, 2025
BUSINESS Industry Appreciates Raise in Minimum NHI Prices, but See It as Mere Drop in Bucket

January 17, 2025
REGULATORY 3 JAK Inhibitors, Wegovy and More Drugs Enjoy First Off-Year Application of Post-Launch Premiums

January 16, 2025
REGULATORY Govt Must Not Let Pro-Innovation Reform of 2024 Go to Waste: Sr Vice Minister

January 15, 2025
BUSINESS SGLT2 Inhibitor Forxiga Braced for Generic Entry in 2025

January 14, 2025

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COLUMN

Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing

By Philip Carrigan

Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…